PAT and QbD changing powder flow analysis says Freeman

By Gareth Macdonald

- Last updated on GMT

Regulatory demands for ‘in process’ performance data have changed the pharma sector’s approach to materials analysis and enhanced the quality of the drugs it produces according to Freeman Technology. spoke with company director of operations Tim Freeman at Interphex 2011 in New York, US, who explained that this change in mindset has had a significant impact on powder flow analysis.

Freeman said that initiatives like PAT and QbD are encouraging industry to consider a material’s characteristics in combination with its intended usage in the manufacturing process, rather than as a separate characteristic.

This change is driving the development of new analysis technologies, Freeman continued, adding that: “The advantage we have in the 21st century is that we can characterise materials… in process relevant ways.

If you have powder in a silo or hopper, rather than just looking at how the density of the powder changes we can measure the sheer strength of the powder to try and simulate the environment the powder is stored in​.”

He added that the ability to quantify powder performance allows drug makers to optimise both formulation development and scale up, improving efficiency and saving time and money.

Related news

Show more

Related products

show more

Shifting the Biomanufacturing Paradigm

Shifting the Biomanufacturing Paradigm

BioContinuum™ Platform - MilliporeSigma | 01-Jul-2020 | Technical / White Paper

Adoption of next generation processing and technologies can enable improvements in productivity by streamlining workflows, reducing the manufacturing plant...

Bio4C™ ProcessPad Software Datasheet

Bio4C™ ProcessPad Software Datasheet

BioContinuum™ Platform - MilliporeSigma | 01-Jul-2020 | Data Sheet

Biopharmaceutical processes are complex and highly variable in nature. This can result in inconsistent and sometimes unpredictable process outcomes. To...

Follow us


View more